The article reports the three-arm randomized triangular clinical trial is presented. It reports that combining ibrutinib with autologous stem-cell transplantation (ASCT) can significantly improve failure-free survival (FFS) compared to ASCT alone, potentially allowing patients with newly diagnosed mantle-cell lymphoma (MCL) to avoid ASCT entirely.